Physician profile

Thomas Kazecki

Internal Medicine · Lake Charles, LA

NPI 1447677810

$402.15

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$245.18

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
E.R. Squibb & Sons, L.L.C. $163.42 2019-2024 Eliquis, Camzyos
Pfizer INC. $86.73 2020-2023
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $33.08 2022-2024 Lifevest
Janssen Pharmaceuticals, INC $31.78 2021
Biomerieux INC $22.29 2021
Abbvie INC. $18.25 2023
Boehringer Ingelheim Pharmaceuticals, INC. $17.29 2019
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $15.71 2023 Xifaxan, Trulance
Aytu Biopharma, INC. $13.60 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Thomas Kazecki

$402.15

in general payments reported 2019-2025

Years
2019-2024
Top company
E.R. Squibb & Sons, L.L.C.

https://glasscript.com/doctor/4443686/thomas-kazecki

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.